Joanne Jenkins Lager - 11 Feb 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Medical Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
11 Feb 2022
Net transactions value
-$110,408
Form type
4
Filing time
14 Feb 2022, 18:59:14 UTC
Previous filing
18 Jan 2022
Next filing
14 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $15,050 +3,500 $4.30 3,500 11 Feb 2022 Direct F1
transaction ITOS Common Stock Sale $70,401 -1,982 -57% $35.52 1,518 11 Feb 2022 Direct F1, F2
transaction ITOS Common Stock Sale $55,058 -1,518 -100% $36.27 0 11 Feb 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (right to buy) Options Exercise $0 -3,500 -1.9% $0.000000 182,438 11 Feb 2022 Common Stock 3,500 $4.30 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.9 to $35.875, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.935 to $36.555, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 One-fourth of the shares subject to the stock option vested on April 1, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date